Last reviewed · How we verify
TetraVax-DV Vaccine-Admixture 4
At a glance
| Generic name | TetraVax-DV Vaccine-Admixture 4 |
|---|---|
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Immunogenicity of the Dengue Virus Vaccine TV005 (TetraVax-DV TV005) in Healthy Adults, Adolescents, and Children in Dhaka, Bangladesh (PHASE2)
- Dengue Controlled Human Infection Model in Dhaka, Bangladesh (PHASE2)
- Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine (PHASE1)
- Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine (PHASE1)
- Evaluation of the Safety and Immune Response of Five Admixtures of a Tetravalent Dengue Virus Vaccine (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: